Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
The Lancet Infectious Diseases (2022) - Comments
pubmed: 35550261  doi: 10.1016/s1473-3099(22)00271-7  issn: 1473-3099  issn: 1474-4457 

Alasdair P S Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A Van Der Klaauw, Nasir Kanji